{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:04:34Z","timestamp":1786982674121,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019507","name":"Ortho Dermatologics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019507","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s13555-024-01264-3","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:02:26Z","timestamp":1726099346000},"page":"2709-2726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of Brodalumab in Patients with Psoriasis and Risk Factors for Treatment Failure: A Review of Post Hoc Analyses"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-5303","authenticated-orcid":false,"given":"Mark G.","family":"Lebwohl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6892-6286","authenticated-orcid":false,"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1351-9165","authenticated-orcid":false,"given":"Andrew F.","family":"Alexis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0762-1251","authenticated-orcid":false,"given":"Edward L.","family":"Lain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-2280","authenticated-orcid":false,"given":"Abby A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"issue":"19","key":"1264_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"4","key":"1264_CR2","first-page":"354","volume":"21","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Menter A, Lain E, Han G, Jacobson A. Long-term skin clearance with brodalumab in patients with psoriasis and inadequate response to prior biologics. J Drugs Dermatol. 2022;21(4):354\u201370.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"1264_CR3","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s13555-022-00746-6","volume":"12","author":"A Menter","year":"2022","unstructured":"Menter A, Bhutani T, Ehst B, Elewski B, Jacobson A. Narrative review of the emerging therapeutic role of brodalumab in difficult-to-treat psoriasis. Dermatol Ther (Heidelb). 2022;12(6):1289\u2013302.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1264_CR4","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.jaad.2023.06.058","volume":"89","author":"JQ Jin","year":"2023","unstructured":"Jin JQ, Cronin A, Roberts-Toler C, et al. Sociodemographic and clinical characteristics associated with multiple biologic failure in psoriasis: a 2015\u20132022 prospective cohort analysis of the CorEvitas psoriasis registry. J Am Acad Dermatol. 2023;89(5):974\u201383.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1264_CR5","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s13555-021-00618-5","volume":"11","author":"G Kokolakis","year":"2021","unstructured":"Kokolakis G, Vadstrup K, Hansen JB, Carrascosa JM. Increased skin clearance and quality of life improvement with brodalumab compared with ustekinumab in psoriasis patients with aggravating lifestyle factors. Dermatol Ther (Heidelb). 2021;11(6):2027\u201342.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1264_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ad.2012.08.003","volume":"105","author":"JM Carrascosa","year":"2014","unstructured":"Carrascosa JM, Rocamora V, Fernandez-Torres RM, et al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr. 2014;105(1):31\u201344.","journal-title":"Actas Dermosifiliogr"},{"issue":"7","key":"1264_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3390\/jcm6070068","volume":"6","author":"M Chehimi","year":"2017","unstructured":"Chehimi M, Vidal H, Eljaafari A. Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases. J Clin Med. 2017;6(7):68.","journal-title":"J Clin Med"},{"issue":"5","key":"1264_CR8","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1172\/JCI117936","volume":"95","author":"GS Hotamisligil","year":"1995","unstructured":"Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95(5):2409\u201315.","journal-title":"J Clin Invest"},{"issue":"9","key":"1264_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/oby.2000.86","volume":"8","author":"L Roytblat","year":"2000","unstructured":"Roytblat L, Rachinsky M, Fisher A, et al. Raised interleukin-6 levels in obese patients. Obes Res. 2000;8(9):673\u20135.","journal-title":"Obes Res"},{"issue":"1","key":"1264_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/ijo.2008.216","volume":"33","author":"M Sumarac-Dumanovic","year":"2009","unstructured":"Sumarac-Dumanovic M, Stevanovic D, Ljubic A, et al. Increased activity of interleukin-23\/interleukin-17 proinflammatory axis in obese women. Int J Obes (Lond). 2009;33(1):151\u20136.","journal-title":"Int J Obes (Lond)"},{"issue":"2","key":"1264_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/JD9.0000000000000155","volume":"4","author":"C Xu","year":"2021","unstructured":"Xu C, Ji J, Su T, Wang H-W, Su Z-L. The Association of psoriasis and obesity: focusing on IL-17A-related immunological mechanisms. Int J Dermatol Venereol. 2021;4(2):116\u201321.","journal-title":"Int J Dermatol Venereol"},{"issue":"11","key":"1264_CR12","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1038\/jid.2008.122","volume":"128","author":"CN Young","year":"2008","unstructured":"Young CN, Koepke JI, Terlecky LJ, Borkin MS, Boyd SL, Terlecky SR. Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol. 2008;128(11):2606\u201314.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"1264_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000348865","volume":"26","author":"A Farkas","year":"2013","unstructured":"Farkas A, Kemeny L. Alcohol, liver, systemic inflammation and skin: a focus on patients with psoriasis. Skin Pharmacol Physiol. 2013;26(3):119\u201326.","journal-title":"Skin Pharmacol Physiol"},{"key":"1264_CR14","first-page":"75","volume":"9","author":"C Svanstrom","year":"2019","unstructured":"Svanstrom C, Lonne-Rahm SB, Nordlind K. Psoriasis and alcohol. Psoriasis (Auckl). 2019;9:75\u20139.","journal-title":"Psoriasis (Auckl)"},{"issue":"6","key":"1264_CR15","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.1365-2133.2011.10526.x","volume":"165","author":"AW Armstrong","year":"2011","unstructured":"Armstrong AW, Armstrong EJ, Fuller EN, Sockolov ME, Voyles SV. Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol. 2011;165(6):1162\u20138.","journal-title":"Br J Dermatol"},{"key":"1264_CR16","first-page":"65","volume":"6","author":"L Naldi","year":"2016","unstructured":"Naldi L. Psoriasis and smoking: links and risks. Psoriasis (Auckl). 2016;6:65\u201371.","journal-title":"Psoriasis (Auckl)"},{"issue":"11","key":"1264_CR17","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.ajpath.2015.07.006","volume":"185","author":"G K\u00f5ks","year":"2015","unstructured":"K\u00f5ks G, Uudelepp M-L, Limbach M, Peterson P, Reimann E, K\u00f5ks S. Smoking-induced expression of the GPR15 gene indicates its potential role in chronic inflammatory pathologies. Am J Pathol. 2015;185(11):2898\u2013906.","journal-title":"Am J Pathol"},{"issue":"11","key":"1264_CR18","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1177\/1535370217703977","volume":"242","author":"S K\u00f5ks","year":"2017","unstructured":"K\u00f5ks S, K\u00f5ks G. Activation of GPR15 and its involvement in the biological effects of smoking. Exp Biol Med (Maywood). 2017;242(11):1207\u201312.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"9","key":"1264_CR19","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s13555-023-00986-0","volume":"13","author":"A Buja","year":"2023","unstructured":"Buja A, Miatton A, Cozzolino C, et al. The prevalent comorbidome at the onset of psoriasis diagnosis. Dermatol Ther (Heidelb). 2023;13(9):2093\u2013105.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1264_CR20","unstructured":"Siliq [package insert]. Bausch Health US, LLC, Bridgewater. 2020."},{"issue":"4","key":"1264_CR21","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/bjd.18327","volume":"182","author":"S Hsu","year":"2020","unstructured":"Hsu S, Green LJ, Lebwohl MG, Wu JJ, Blauvelt A, Jacobson AA. Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials. Br J Dermatol. 2020;182(4):880\u20138.","journal-title":"Br J Dermatol"},{"issue":"14","key":"1264_CR22","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u201328.","journal-title":"N Engl J Med"},{"issue":"2","key":"1264_CR23","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jdv.15277","volume":"33","author":"LM Sawyer","year":"2019","unstructured":"Sawyer LM, Cornic L, Levin LA, Gibbons C, Moller AH, Jemec GB. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol. 2019;33(2):355\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1264_CR24","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","volume":"156","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258\u201369.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1264_CR25","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjd.13013","volume":"171","author":"AB Kimball","year":"2014","unstructured":"Kimball AB, Leonardi C, Stahle M, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014;171(1):137\u201347.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1264_CR26","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.jaad.2009.09.053","volume":"63","author":"S Bremmer","year":"2010","unstructured":"Bremmer S, Van Voorhees AS, Hsu S, et al. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;63(6):1058\u201369.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1264_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1264_CR28","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1590\/S0365-05962011000200008","volume":"86","author":"AA Duarte","year":"2011","unstructured":"Duarte AA, Chehin FB. Moderate to severe psoriasis treated with infliximab\u201453 patients: patients profile, efficacy and adverse effects. An Bras Dermatol. 2011;86(2):257\u201363.","journal-title":"An Bras Dermatol"},{"key":"1264_CR29","first-page":"111","volume":"2","author":"JD Bahner","year":"2009","unstructured":"Bahner JD, Cao LY, Korman NJ. Biologics in the management of psoriasis. Clin Cosmet Investig Dermatol. 2009;2:111\u201328.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"1264_CR30","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","volume":"41","author":"F Pirro","year":"2021","unstructured":"Pirro F, Caldarola G, Chiricozzi A, et al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917\u201325.","journal-title":"Clin Drug Investig"},{"issue":"10","key":"1264_CR31","doi-asserted-by":"publisher","first-page":"300060520964024","DOI":"10.1177\/0300060520964024","volume":"48","author":"H Zhou","year":"2020","unstructured":"Zhou H, Wu R, Kong Y, Zhao M, Su Y. Impact of smoking on psoriasis risk and treatment efficacy: a meta-analysis. J Int Med Res. 2020;48(10):300060520964024.","journal-title":"J Int Med Res"},{"issue":"10","key":"1264_CR32","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2340\/00015555-3221","volume":"99","author":"F Anzengruber","year":"2019","unstructured":"Anzengruber F, Augustin M, Radtke MA, et al. Smoking does not alter the therapy response to systemic anti-psoriatic therapies: a two-country, multi-centre, prospective, non-interventional study. Acta Derm Venereol. 2019;99(10):871\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"1264_CR33","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/bjd.16776","volume":"180","author":"RB Warren","year":"2019","unstructured":"Warren RB, Marsden A, Tomenson B, et al. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol. 2019;180(5):1069\u201376.","journal-title":"Br J Dermatol"},{"key":"1264_CR34","unstructured":"Yarkan H, Kenar G, Capar S, et al. The effect of smoking on response to tumour necrosis factor-alpha inhibitor treatment in psoriatic arthritis patients: results from the Turkbio registry. In: Abstract 2615 presented at: 2018 ACR\/ARHP Annual Meeting; October 19\u201324, 2018; Chicago, IL."},{"issue":"2","key":"1264_CR35","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5021\/ad.2013.25.2.156","volume":"25","author":"AK Gupta","year":"2013","unstructured":"Gupta AK, Pandey SS, Pandey BL. Effectiveness of conventional drug therapy of plaque psoriasis in the context of consensus guidelines: a prospective observational study in 150 patients. Ann Dermatol. 2013;25(2):156\u201362.","journal-title":"Ann Dermatol"},{"issue":"8","key":"1264_CR36","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3390\/jpm11080752","volume":"11","author":"MM Constantin","year":"2021","unstructured":"Constantin MM, Bucur S, Mutu CC, et al. The impact of smoking on psoriasis patients with biological therapies in a Bucharest hospital. J Pers Med. 2021;11(8):752.","journal-title":"J Pers Med"},{"issue":"1","key":"1264_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/jid.2013.326","volume":"134","author":"E Edson-Heredia","year":"2014","unstructured":"Edson-Heredia E, Sterling KL, Alatorre CI, et al. Heterogeneity of response to biologic treatment: perspective for psoriasis. J Invest Dermatol. 2014;134(1):18\u201323.","journal-title":"J Invest Dermatol"},{"issue":"suppl 3","key":"1264_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/jdv.12164","volume":"27","author":"E Brenaut","year":"2013","unstructured":"Brenaut E, Horreau C, Pouplard C, et al. Alcohol consumption and psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2013;27(suppl 3):30\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1264_CR39","first-page":"105","volume":"99","author":"F Gruber","year":"1999","unstructured":"Gruber F, Simonic E, Jonjic A, Lenkovic M, Peharda V. Alcohol consumption and smoking habits in patients with psoriasis. Acta Dermatovenereologica APA. 1999;99(3):105\u20139.","journal-title":"Acta Dermatovenereologica A.P.A."},{"issue":"6","key":"1264_CR40","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s40257-022-00713-z","volume":"23","author":"N Kearney","year":"2022","unstructured":"Kearney N, Kirby B. Alcohol and psoriasis for the dermatologist: know, screen, intervene. Am J Clin Dermatol. 2022;23(6):881\u201390.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1264_CR41","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/bjd.20577","volume":"185","author":"IYK Iskandar","year":"2021","unstructured":"Iskandar IYK, Lunt M, Thorneloe RJ, et al. Alcohol misuse is associated with poor response to systemic therapies for psoriasis: findings from a prospective multicentre cohort study. Br J Dermatol. 2021;185(5):952\u201360.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1264_CR42","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/09546634.2020.1763240","volume":"33","author":"O Zorlu","year":"2022","unstructured":"Zorlu O, Bulbul Baskan E, Yazici S, et al. Predictors of drug survival of biologic therapies in psoriasis patients. J Dermatolog Treat. 2022;33(1):437\u201342.","journal-title":"J Dermatolog Treat"},{"issue":"5","key":"1264_CR43","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.4049\/jimmunol.1201505","volume":"190","author":"A Johnston","year":"2013","unstructured":"Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190(5):2252\u201362.","journal-title":"J Immunol"},{"issue":"1","key":"1264_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaci.2020.12.628","volume":"148","author":"J Borowczyk","year":"2021","unstructured":"Borowczyk J, Shutova M, Brembilla NC, Boehncke WH. IL-25 (IL-17E) in epithelial immunology and pathophysiology. J Allergy Clin Immunol. 2021;148(1):40\u201352.","journal-title":"J Allergy Clin Immunol"},{"key":"1264_CR45","doi-asserted-by":"publisher","first-page":"1186455","DOI":"10.3389\/fimmu.2023.1186455","volume":"14","author":"NC Brembilla","year":"2023","unstructured":"Brembilla NC, Boehncke WH. Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies. Front Immunol. 2023;14:1186455.","journal-title":"Front Immunol"},{"issue":"3","key":"1264_CR46","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1365-2613.2009.00669.x","volume":"90","author":"R Heidenreich","year":"2009","unstructured":"Heidenreich R, Rocken M, Ghoreschi K. Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol. 2009;90(3):232\u201348.","journal-title":"Int J Exp Pathol"},{"key":"1264_CR47","unstructured":"Bimzelx [package insert]. UCB, Inc, Smyrna. 2023."},{"key":"1264_CR48","unstructured":"Cosentyx [package insert]. Novartis Pharmaceuticals Corporation, East Hanover. 2016."},{"key":"1264_CR49","unstructured":"Taltz [package insert]. Eli Lilly and Company, Indianapolis. 2024."},{"issue":"2","key":"1264_CR50","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bjd.17318","volume":"180","author":"RG Langley","year":"2019","unstructured":"Langley RG, Armstrong AW, Lebwohl MG, et al. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials. Br J Dermatol. 2019;180(2):306\u201314.","journal-title":"Br J Dermatol"},{"key":"1264_CR51","first-page":"123","volume":"11","author":"P Hampton","year":"2021","unstructured":"Hampton P, Borg E, Hansen JB, Augustin M. Efficacy of brodalumab and guselkumab in patients with moderate-to-severe plaque psoriasis who are inadequate responders to ustekinumab: a matching adjusted indirect comparison. Psoriasis (Auckl). 2021;11:123\u201331.","journal-title":"Psoriasis (Auckl)"},{"issue":"1","key":"1264_CR52","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","volume":"178","author":"RG Langley","year":"2018","unstructured":"Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114\u201323.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1264_CR53","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00403-019-01907-y","volume":"311","author":"I Gasslitter","year":"2019","unstructured":"Gasslitter I, Kirsten N, Augustin M, et al. Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study. Arch Dermatol Res. 2019;311(5):421\u20134.","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"1264_CR54","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jaad.2019.05.007","volume":"81","author":"G Kimmel","year":"2019","unstructured":"Kimmel G, Chima M, Kim HJ, et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol. 2019;81(3):857\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1264_CR55","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jaad.2020.11.013","volume":"84","author":"J Yeung","year":"2021","unstructured":"Yeung J, Vender R, Turchin I, et al. Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors. J Am Acad Dermatol. 2021;84(4):1169\u201371.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1264_CR56","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1080\/09546634.2020.1716932","volume":"32","author":"C Kromer","year":"2021","unstructured":"Kromer C, Wilsmann-Theis D, Gerdes S, et al. Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker\u2014a retrospective multicenter study. J Dermatolog Treat. 2021;32(8):878\u201382.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1264_CR57","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15106","volume":"34","author":"N Loft","year":"2021","unstructured":"Loft N, Bregnhoj A, Fage S, et al. Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis. Dermatol Ther. 2021;34(6):e15106.","journal-title":"Dermatol Ther"},{"issue":"3","key":"1264_CR58","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/12034754231168851","volume":"27","author":"V Gaudet","year":"2023","unstructured":"Gaudet V, Yap B, Hassan S, Barbeau M. Brodalumab for plaque psoriasis: a Canadian real-world experience at 2-years post-launch. J Cutan Med Surg. 2023;27(3):226\u201335.","journal-title":"J Cutan Med Surg"},{"issue":"6","key":"1264_CR59","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jaad.2014.08.039","volume":"71","author":"K Papp","year":"2014","unstructured":"Papp K, Leonardi C, Menter A, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71(6):1183-90.e3.","journal-title":"J Am Acad Dermatol"},{"key":"1264_CR60","unstructured":"World Health Organization. Obesity and overweight. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight. Accessed June 5, 2024."},{"key":"1264_CR61","unstructured":"World Health Organization. Tobacco. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/tobacco. Accessed June 5, 2024."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01264-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01264-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01264-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T13:07:21Z","timestamp":1728997641000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01264-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1264"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01264-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mark G. Lebwohl is an employee of Mount Sinai; has received research funding from AbbVie, Amgen, Arcutis Biotherapeutics, Avotres, Boehringer Ingelheim, Cara Therapeutics, Clexio Biosciences, Dermavant Sciences, Incyte, Inozyme, Janssen, Lilly, Ortho Dermatologics (a division of Bausch Health Companies Inc), Pfizer, Sanofi-Regeneron, and UCB; and has served as a consultant for Almirall, AltruBio, AnaptysBio, Apogee, Arcutis Biotherapeutics, AstraZeneca, Atomwise, Avotres Therapeutics, Brickell Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, Dermsquared, EPI Health, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica. April W. Armstrong has served as a research investigator, scientific advisor and\/or speaker to AbbVie, Almirall, Arcutis Biotherapeutics, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant Sciences, Dermira, EPI Health, Incyte, Janssen, LEO Pharma, Lilly, Nimbus, Novartis, Ortho Dermatologics (a division of Bausch Health Companies Inc), Pfizer, Sanofi-Regeneron, Sun Pharmaceuticals, and UCB. Andrew F. Alexis has received research funding from AbbVie, Amgen, Arcutis Biotherapeutics, Castle Biosciences, Dermavant Sciences, Galderma, and LEO Pharma; has served as a consultant or advisory board member for AbbVie, Almirall, Allergan, Alphaeon, Alphyn, Amgen, Apogee, Arcutis Biotherapeutics, Bausch Health Companies Inc, Beiersdorf, Bristol-Myers Squibb, Canfield Scientific, Cara Therapeutics, Castle Biosciences, Cutera, Dermavant Sciences, EPI Health, Galderma, Incyte, Janssen, Lilly, L\u2019Oreal, Ortho Dermatologics (a division of Bausch Health Companies Inc), Pfizer, Sanofi-Regeneron, Swiss American, UCB, and VisualDx; has served as a speaker for Bristol-Myers Squibb, Johnson & Johnson, Janssen, L\u2019Oreal, Regeneron, and Sanofi-Genzyme; and has received royalties from Springer, Wiley-Blackwell, and Wolters Kluwer Health and equipment from Aerolase. Edward L. Lain has served as an investigator, speaker, consultant, or advisory board member for AbbVie, Aclaris Therapeutics, AlfaSigma, Allergan, Almirall, Arcutis Biotherapeutics, AstraZeneca, Athenix, Biofrontera, Biopelle, BioPharmX, Biorasi, Brickell Biotech, Bristol-Myers Squibb, Cassiopea S.p.A, Castle Biosciences, Celgene, Cellceutix, ChemoCentryx, Concert Pharma, Cutanea, Dermavant Sciences, Dermira, Dermtech, Dow, Dr. Reddy's Laboratories, Endo Pharma, EPI Health, Evelo, Gage Development Company, Galderma Laboratories, Galderma, Hovione, Incyte, Janssen, Johnson & Johnson, Kadmon Corporation, La Roche-Posay, LEO Pharma, Lilly, MedImmune, Menlo Therapeutics, Mindera, Moleculin, Neothetics, Nielsen Holdings N.V, Novartis, Ortho Dermatologics (a division of Bausch Health Companies Inc), Pierre Fabre, Pfizer, Promius Pharma, Sanofi, Sebacia, Sienna Labs, SkinCeuticals, Sol\u2013Gel Technologies, Sun Pharmaceuticals, Symatese, Timber Pharma, UCB, Valeant Pharmaceuticals North America, and Vyne Therapeutics. Abby A. Jacobson is an employee of Bausch Health Companies Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}